240 related articles for article (PubMed ID: 27214767)
61. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
62. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
Sakthiswary R; Shaharir SS; Mohd Said MS; Asrul AW; Shahril NS
Int J Rheum Dis; 2014 Nov; 17(8):872-7. PubMed ID: 25292482
[TBL] [Abstract][Full Text] [Related]
63. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
Raaschou P; Frisell T; Askling J;
Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
[TBL] [Abstract][Full Text] [Related]
64. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha.
Den Broeder AA; Creemers MC; van Gestel AM; van Riel PL
Rheumatology (Oxford); 2002 Jun; 41(6):638-42. PubMed ID: 12048289
[TBL] [Abstract][Full Text] [Related]
65. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
66. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
[TBL] [Abstract][Full Text] [Related]
67. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
68. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
69. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
71. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
[TBL] [Abstract][Full Text] [Related]
72. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
73. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
74. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis.
Phillips C; Zeringue AL; McDonald JR; Eisen SA; Ranganathan P
PLoS One; 2015; 10(11):e0143286. PubMed ID: 26599370
[TBL] [Abstract][Full Text] [Related]
75. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
76. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
77. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial.
Dougados M; Huizinga TW; Choy EH; Bingham CO; Aassi M; Bernasconi C
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1762-6. PubMed ID: 26037777
[TBL] [Abstract][Full Text] [Related]
79. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
Manders SH; Kievit W; Braakman-Jansen AL; Brus HL; Hendriks L; Fransen J; van de Laar MA; van Riel PL
J Rheumatol; 2014 Jul; 41(7):1263-9. PubMed ID: 24833758
[TBL] [Abstract][Full Text] [Related]
80. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
